MENU
+Compare
SCYX
Stock ticker: NASDAQ
AS OF
Apr 10, 04:53 PM (EDT)
Price
$0.89
Change
+$0.03 (+3.49%)
Capitalization
55.88M

SCYX SCYNEXIS Forecast, Technical & Fundamental Analysis

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs... Show more

SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for SCYX with price predictions
Apr 09, 2025

SCYX's RSI Oscillator recovers from oversold territory

The RSI Indicator for SCYX moved out of oversold territory on April 09, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In of the 41 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where SCYX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where SCYX advanced for three days, in of 241 cases, the price rose further within the following month. The odds of a continued upward trend are .

SCYX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SCYX as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SCYX turned negative on April 01, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

SCYX moved below its 50-day moving average on March 18, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCYX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SCYX entered a downward trend on March 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.766) is normal, around the industry mean (61.171). P/E Ratio (1.065) is within average values for comparable stocks, (90.174). SCYX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.987). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (0.511) is also within normal values, averaging (20.123).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SCYX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCYX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

SCYX is expected to report earnings to rise 133.33% to -20 cents per share on May 08

SCYNEXIS SCYX Stock Earnings Reports
Q1'25
Est.
$-0.21
Q4'24
Beat
by $0.06
Q3'24
Beat
by $0.08
Q2'24
Missed
by $0.15
Q1'24
Beat
by $0.19
The last earnings report on March 12 showed earnings per share of -9 cents, beating the estimate of -15 cents. With 68.43K shares outstanding, the current market capitalization sits at 55.88M.
A.I. Advisor
published General Information

General Information

a company which engages in discovery, development and commercialization of novel anti infectives

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
1 Evertrust Plaza
Phone
+1 201 884-5485
Employees
36
Web
https://www.scynexis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARWR11.801.81
+18.12%
Arrowhead Pharmaceuticals
MUFG11.841.05
+9.73%
Mitsubishi UFJ Financial Group
AUDC8.890.73
+8.88%
AudioCodes Ltd
PSN63.153.79
+6.38%
Parsons Corp
NEUE6.420.07
+1.10%
NeueHealth

SCYX and Stocks

Correlation & Price change

A.I.dvisor tells us that SCYX and TXMD have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and TXMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
+7.07%
TXMD - SCYX
31%
Poorly correlated
N/A
CRON - SCYX
29%
Poorly correlated
+5.78%
AKAN - SCYX
29%
Poorly correlated
N/A
ACET - SCYX
27%
Poorly correlated
-13.33%
OGI - SCYX
27%
Poorly correlated
+8.52%
More